Boston Scientific exceeded projections for its third quarter after posting stronger than expected revenues, the Wall Street Journal reports.
Here's what you should know.
1. Boston Scientific revised its year forecast to between $1.09 and $1.11 per share on a revenue of $8.34 billion to $8.39 billion. It previously was at $1.07 to $1.11 per share on a revenue of $8.27 billion to $8.37 billion.
2. Its also adjusted its fourth quarter earnings to between $0.27 to $0.29 per share on a revenue of $2.14 billion to $2.19 billion. Analysts pegged its Q4 ratings at $0.29 per share on $2.15 billion in revenue.
3. Boston Scientific's MedSurg saw a 15 percent increase in sales during Q3 to $753 million.
4. Boston Scientific expects to complete its acquisition of EndoChoice by the end of the fourth quarter.
5. The company reported a profit of $228 million during Q3. Last year it reported a loss of $198 million.
6. Cardiovascular products remain its market leader. Sales grew 13 percent to $825 million in Q3.